Could Huggies and Tylenol be a good fit? Kimberly-Clark is buying Kenvue for $48 billion

By James Rogers

Kenvue's stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark's stock tumbled

Consumer goods giant Kimberly-Clark Corp. is buying Tylenol maker Kenvue Inc. in a deal valued at $48.7 billion.

Consumer-goods giant Kimberly-Clark Corp. announced Monday a deal to buy Kenvue Inc., ending months of speculation about the future of the embattled maker of Tylenol, Band-Aid and Listerine.

Even though Kimberly-Clark's per-share buyout bid implies a 46% premium to Friday's closing price for the stock, the company is still getting Kenvue for a discount to what it was worth when it went public about 21/2 years ago.

Kimberly-Clark is adding a company at the intersection of consumer packaged goods and healthcare, Chief Executive Mike Hsu said in a statement. It comes as the company is looking to pivot its portfolio to "higher-growth, higher-margin" businesses.

With the acquisition, expected to close in the second half of 2026, Kimberly-Clark can serve consumers at every stage of life with "iconic brands," as consumers are increasingly prioritizing health and wellness.

The cash-and-stock transaction deal for Kenvue implies a $40.3 billion market capitalization for Kenvue (KVUE), based on the closing price of Kimberly-Clark's (KMB) stock on Oct. 31. The total value of the deal, including debt, was $48.7 billion.

When Kenvue was spun off from Johnson & Johnson (JNJ) in May 2023 through an initial public offering, the pricing of the IPO had implied a market cap for the company, at the time, of $48 billion. The company had long-term debt of about $7.7 billion.

Under terms of the deal, Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly-Clark shares for each Kenvue share held at closing on Oct. 31, for a total consideration to Kenvue shareholders of $21.01 per share, based on Friday's closing prices. That's a 46.2% premium to Friday's closing price of $14.37, but less than Kenvue's IPO pricing in May 2023 of $22 a share.

Kenvue's stock was soaring in Monday trading, up more than 14.8% shortly after 1 p.m. to lead the S&P 500 index's SPX early gainers. That would roughly match the record one-day gain of 14.7% seen on Aug. 6, 2024.

Meanwhile, shares of Kimberly-Clark, the maker of Huggies diapers, tumbled 13.4%, putting it on track to suffer the biggest one-day selloff since a record 25.4% drop on Oct. 19, 1987. Mergers involving stock can often hurt the acquirer's stock price, as they dilute the ownership of existing shareholders. But the size of the stock's selloff suggests investors may also have other concerns about the deal.

Kenvue has not had the easiest time after the spinoff. In July, the company announced a review of strategic alternatives as it wrestled with declining sales. The following month, Kenvue lowered its full-year sales outlook, citing a "dynamic external environment."

More recently, Kenvue's stock took a hit after U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and President Donald Trump claimed that Tylenol was linked to autism. The company responded, saying that "sound science clearly shows" that taking acetaminophen, the generic name for Tylenol, does not cause autism.

And while RFK Jr. has walked back some of the claims recently, the stock was still hovering just above the Oct. 16 record closing low of $14.11.

"We truly believe this transaction with Kimberly-Clark will bring greater value to our shareholders, create new and different potential growth opportunities for our talented employees and deliver even more benefits to our customers and consumers," Kenvue Chief Executive Kirk Perry said in the statement.

Hsu will be the CEO of the combined company, which will maintain Kimberly-Clark's headquarters in Irving, Texas.

Separately, Kenvue also reported third-quarter results on Monday, with sales declining 3.5% year-over-year to $3.764 billion, below the FactSet consensus estimate $3.820 billion. On an adjusted basis, Kenvue earned 28 cents a share, which was the same as last year, but above expectations of 26 cents a share.

Kimberly-Clark shares have shed 23.7% in 2025, while Kenvue's stock is down 22.8%, compared with the S&P 500 index's SPX gain of 16.6%.

-James Rogers

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

11-03-25 1326ET